| Autor: |
Lopez‐Pereira, P., Romero‐Dominguez, S., Martin‐Moro, F., Caballero‐Gonzalez, A. C., Lopez‐Garcia, A., Cruz‐Benito, B. de la, Franch‐Sarto, M., Cruz‐Vicente, F. de la, Lopez‐Marin, J., Pinzon‐Marino, S., Jimenez‐Ubieto, A., Cabirta‐Touzon, A., Gutierrez‐Gutierrez, N. C., Lis‐Chulvi, M. J., Puyuelo, A., Muntañola‐Prat, A., Penedo‐Coello, A., Encuentra‐Marti, M. T., Mercadal‐Vilchez, S. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p401-401, 1p |
| Abstrakt: |
At the time of analysis, 21 patients had died and 8 patients had relapsed after ASCT. B Conclusions: b This is a "real-life" study assessing the feasibility and efficacy of the MATRix regimen followed by ASCT as frontline therapy in immunocompetent PCNSL patients, performed on behalf of GELTAMO group. Causes of death were: progression, 13 patients, pneumonia, 7 and cerebral hemorrhage in 1 patient. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text